Emcure Pharmaceuticals Ltd IPO

About Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited as a private limited company under the provisions of the Companies Act, 1956, pursuant to a certificate of incorporation dated April 16, 1981, issued by the Registrar of Companies, Maharashtra at Bombay. The Company became a deemed public company under section 43A (1A) of the Companies Act, 1956 with effect from July 1, 1993 and the word `Private' was removed from the name of the Company and the certificate of incorporation of the Company was endorsed by the Registrar of Companies, Maharashtra at Bombay to that effect. Subsequently, the Company was converted from a deemed public company into a public company upon amendment of section 43A of the Companies Act, 1956 by the Companies Amendment Act, 2000 and the name of the Company was changed to `Emcure Pharmaceuticals Limited', pursuant to its Shareholders resolution dated August 20, 2001 and a certificate of change of name was issued by the RoC on September 18, 2001.

The global pharmaceutical market is expected to sustain growth at a compound annual growth rate of approximately 5.0% to 5.5% between the calendar years 2023 and 2028, to reach approximately US$1,900 billion (approximately Rs.157 trillion) to US$1,950 billion (approximately Rs.161 trillion) in the calendar year 2028. The Indian domestic formulations segment (consumption) is expected to grow at a CAGR of approximately 8% to 9% between the Financial Years 2024 and 2029, to reach approximately Rs.2.9 trillion to Rs.3.0 trillion in the Financial Year 2029, aided by strong demand from the rising incidence of chronic diseases, increased awareness and access to quality healthcare.

Emcure Pharmaceuticals Limited is an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company is a research and development driven company with a differentiated product portfolio that includes orals, injectables and biotherapeutics, which has enabled it to reach a range of target markets across over 70 countries, with a strong presence in India, Europe and Canada. In India, it is present across acute and chronic therapeutic areas, and its key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, blood-related and oncology/anti-neoplastics.

Strengths

Risk

Strategy